↓ Skip to main content

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, June 2022

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
5 X users

Readers on

mendeley
60 Mendeley